Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 796 across all filing types
Latest filing 2026-03-27 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Regulatory Filings Classification · 1% confidence The document is a detailed press release by Pharming Group announcing a positive CHMP opinion from the EMA for its drug Joenja® (leniolisib) and outlining the regulatory process and next steps. It contains forward‐looking statements but is not a financial earnings announcement, management commentary on results, a formal regulatory filing like an annual report, or a meeting notice. Instead, it is a general regulatory update regarding the status of a marketing authorization application. This best matches our “Regulatory Filings (RNS)” category as a miscellaneous regulatory announcement.
2026-03-27 English
6-K - Pharming Group N.V. (0001828316) (Filer)
Foreign Filer Report
2026-03-24 English
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing regulatory approval of a pharmaceutical product in Japan. It is not an earnings release, board/management change, financing update, or formal financial report. It does not contain financial statements or voting results, nor is it a transcript or shareholder document. Therefore, it falls into the fallback category for miscellaneous regulatory announcements (RNS).
2026-03-24 Dutch
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing regulatory approval of a pharmaceutical product in Japan. It contains no financial results, no share transactions, no meeting materials, no capital or dividend notices, and no statistical report attachments. It does not fit any specialized category (e.g., earnings release, M&A, interim report), and is a general regulatory/market announcement. Therefore, it falls into the fallback category: Regulatory Filings (RNS).
2026-03-24 English
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Earnings Release Classification · 1% confidence The document is a detailed financial results announcement from Pharming Group N.V. for the fourth quarter and full year 2025. It contains comprehensive financial tables (income statement, balance sheet, segment revenue), management commentary on performance, product-specific updates (RUCONEST and Joenja), and future outlooks. While it is presented as a press release, its length (over 40,000 characters) and the inclusion of full financial statements and detailed operational analysis qualify it as an Earnings Release (ER) rather than a simple report publication announcement (RPA). Q4 2025
2026-03-12 Dutch
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Earnings Release Classification · 1% confidence The document is a comprehensive financial results announcement from Pharming Group N.V. for the fourth quarter and full year 2025. It includes detailed financial tables (Consolidated Statement of Income, Balance Sheet, Segment information), management commentary, operational highlights, and forward-looking guidance. While it is presented as a press release, it contains the full scope of preliminary financial results for the period, which aligns with the definition of an Earnings Release (ER) as it provides the initial announcement of quarterly/periodical financial results with key highlights and financial data. FY 2025
2026-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.